ReviewFrontiers in medicine2017

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Luis Corrales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.